Suppr超能文献

经皮腔内血管成形术治疗药物难治性不稳定型心绞痛的大隐静脉移植血管病变

Percutaneous transluminal angioplasty of saphenous vein grafts for medically refractory unstable angina.

作者信息

Morrison D A, Crowley S T, Veerakul G, Barbiere C C, Grover F, Sacks J

机构信息

Cardiology Section, Denver Department of Veterans Affairs Medical Center, Colorado.

出版信息

J Am Coll Cardiol. 1994 Apr;23(5):1066-70. doi: 10.1016/0735-1097(94)90591-6.

Abstract

OBJECTIVES

We attempted to answer the question, Is balloon angioplasty a reasonable alternative to repeat coronary artery bypass graft surgery in patients with previous coronary bypass graft surgery, medically refractory unstable angina and vein graft lesions?

BACKGROUND

Patients with medically refractory unstable angina need revascularization. Patients with previous coronary artery bypass graft surgery and medically refractory angina are at "high risk" for adverse outcomes with repeat coronary bypass graft surgery. Conversely, patients with angioplasty of old vein grafts are also at "high risk" for adverse outcomes.

METHODS

Balloon angioplasty of 89 lesions in saphenous vein grafts was performed in 75 consecutive patients with medically refractory unstable angina. Of these 75 patients, 24 (32%) had myocardial infarct within 30 days, 23 (31%) had left ventricular ejection fraction < 0.35, and 50 (67%) had major comorbidity. Patients underwent standard balloon angioplasty with aggressive use of intravenous and intracoronary heparin, urokinase, nitroglycerin, oral aspirin, calcium channel blocking agents and coumadin.

RESULTS

Angiographic success (reduction of stenosis < or = 50% without major complication) was seen in 84 of 89 lesions. Clinical success (angiographic success plus hospital discharge without major complication) was seen in 70 of 75 patients. During index hospitalization, two patients (3%) died, two (3%) had nonfatal infarcts, and one (1%) had emergency reoperation (coronary bypass graft surgery). In late follow up (3 to 66 months), 14 (20%) patients were lost to follow-up, 17 (23%) had repeat percutaneous transluminal coronary angioplasty, 2 (3%) had late bypass graft reoperation, 18 (25%) had late death, and 1 (< 1%) had a heart transplant. Of the 41 patients alive after one or more angioplasties, 25 have little or no angina, and 16 have occasional or more angina. We compared long-term survival rate in these 75 patients with a cohort of patients with high risk, unstable angina from the Veterans Affairs Surgical Registry (2,570 patients). The 30-day survival rate was better in patients with coronary angioplasty (97% vs. 92%, p < 0.05), but by 6 months there was no difference, and by 5 years a trend toward a higher survival rate with coronary artery bypass graft surgery was seen.

CONCLUSIONS

Balloon angioplasty of saphenous vein grafts with aggressive adjunctive pharmacotherapy is a reasonable alternative to repeat coronary bypass graft surgery in patients with medically refractory unstable angina, previous coronary bypass graft surgery and saphenous vein narrowing.

摘要

目的

我们试图回答这个问题,即对于曾接受过冠状动脉搭桥手术、药物治疗无效的不稳定型心绞痛以及静脉移植物病变的患者,球囊血管成形术是否是再次冠状动脉搭桥手术的合理替代方案?

背景

药物治疗无效的不稳定型心绞痛患者需要进行血运重建。曾接受过冠状动脉搭桥手术且药物治疗无效的心绞痛患者再次进行冠状动脉搭桥手术时出现不良后果的风险为“高风险”。相反,对陈旧静脉移植物进行血管成形术的患者出现不良后果的风险同样为“高风险”。

方法

对75例连续的药物治疗无效的不稳定型心绞痛患者的89处大隐静脉移植物病变进行了球囊血管成形术。在这75例患者中,24例(32%)在30天内发生心肌梗死,23例(31%)左心室射血分数<0.35,50例(67%)有严重合并症。患者接受了标准球囊血管成形术,并积极使用静脉内和冠状动脉内肝素、尿激酶、硝酸甘油、口服阿司匹林、钙通道阻滞剂和香豆素。

结果

89处病变中有84处造影成功(狭窄减少≤50%且无重大并发症)。75例患者中有70例临床成功(造影成功且出院时无重大并发症)。在首次住院期间,2例患者(3%)死亡,2例(3%)发生非致命性梗死,1例(1%)接受了急诊再次手术(冠状动脉搭桥手术)。在后期随访(3至66个月)中,14例(20%)患者失访,17例(23%)接受了再次经皮冠状动脉腔内血管成形术,2例(3%)接受了后期搭桥手术,18例(25%)死亡,1例(<1%)接受了心脏移植。在接受一次或多次血管成形术后仍存活的41例患者中,25例几乎没有或没有心绞痛,16例偶尔或经常有心绞痛。我们将这75例患者的长期生存率与退伍军人事务外科登记处的一组高危、不稳定型心绞痛患者(2570例)进行了比较。冠状动脉血管成形术患者的30天生存率更高(97%对92%,p<0.05),但到6个月时没有差异,到5年时,冠状动脉搭桥手术的生存率有升高趋势。

结论

对于药物治疗无效的不稳定型心绞痛、曾接受过冠状动脉搭桥手术且大隐静脉狭窄的患者,积极辅助药物治疗的大隐静脉移植物球囊血管成形术是再次冠状动脉搭桥手术的合理替代方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验